Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice

Stem Cells
Laurence PirsonYves Beguin

Abstract

There is potential interest for combining allogeneic hematopoietic cell transplantation (HCT), and particularly allogeneic HCT with a nonmyeloablative regimen, to the tyrosine kinase inhibitor imatinib (Glivec; Novartis, Basel, Switzerland, http://www.novartis.com) in order to maximize anti-leukemic activity against Philadelphia chromosome-positive leukemias. However, because imatinib inhibits c-kit, the stem cell factor receptor, it could interfere with bone marrow engraftment. In this study, we examined the impact of imatinib on normal progenitor cell function. Imatinib decreased the colony-forming capacity of mobilized peripheral blood human CD133(+) cells but not that of long-term culture-initiating cells. Imatinib also decreased the proliferation of cytokine-stimulated CD133(+) cells but did not induce apoptosis of these cells. Expression of very late antigen (VLA)-4, VLA-5, and CXCR4 of CD133(+) cells was not modified by imatinib, but imatinib decreased the ability of CD133(+) cells to migrate. Finally, imatinib did not decrease engraftment of CD133(+) cells into irradiated nonobese diabetic/severe combined immunodeficient/beta2m(null) mice conditioned with 3 or 1 Gy total body irradiation. In summary, our results suggest...Continue Reading

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Jul 1, 1991·The Journal of Experimental Medicine·M OgawaS Nishikawa
Apr 21, 1999·Experimental Hematology·J P Lévesque, P J Simmons
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J MauroBrian J Druker
Apr 3, 2002·Trends in Molecular Medicine·Brian J Druker
Oct 31, 2002·British Journal of Haematology·Kwee L YongDavid C Linch
May 21, 2003·Annals of Internal Medicine·Razelle KurzrockMoshe Talpaz
Sep 13, 2003·Blood·Kerol BartolovicTim H Brümmendorf
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Issa F KhouriRichard E Champlin
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric BaronRainer Storb
Apr 7, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Frédéric BaronRainer Storb
Aug 10, 2005·Trends in Molecular Medicine·Mohamad MohtyBéatrice Gaugler

❮ Previous
Next ❯

Citations

Oct 1, 1994·Pharmacology & Therapeutics·J Baselga, J Mendelsohn
Jan 5, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·B RíhováK Ulbrich
Feb 14, 2015·Drug and Chemical Toxicology·Navneet Kumar YadavR K Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.